Curevac : Curevac and European Commission in Advanced Discussions to Supply up to 405 Million Doses of Potential MRNA-Based COVID-19 Vaccine

TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / August 20, 2020 / CureVac, a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and the European Commission have today concluded exploratory talks outlining an Advanced Purchase Agreement (APA) for our potential mRNA-based COVID-19 vaccine.

The envisaged contract with the European Commission is intended to provide all EU Member States with up to 225 million doses and an option for an additional purchase of 180 million doses, to be supplied once our mRNA-based vaccine has proven to be safe and effective against COVID-19.

Our mRNA-based vaccine candidate to prevent SARS-CoV-2 infection is currently in a Phase 1 clinical trial at different study sites in Germany and Belgium. The aim is to determine the optimal dose as well as to evaluate the safety and immunological profile of the vaccine in humans. We are expecting first results in early Q4 2020. Based on the results of the Phase 1 clinical trial, we plan to initiate a Phase 2b/3 clinical trial also in Q4 2020.

Dr. Franz-Werner Haas, Chief Executive Officer of CureVac, said: “In the current pandemic, we are very pleased to further strengthen the European Commission’s endeavor to provide rapid access to a safe and effective vaccine against the COVID-19 virus across Europe and beyond. Assuming positive results from our ongoing clinical trials and approval from the regulatory authorities, we are fully committed to ensure broad access to our vaccine.”

About CureVac

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of rare diseases. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

CureVac’s Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections CureVac regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CureVac Media Contact
Thorsten Schüller, Director Corporate Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com

CureVac Investor Relation Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com

SOURCE: CureVac AG

View source version on accesswire.com:
https://www.accesswire.com/602567/Curevac-Curevac-and-European-Commission-in-Advanced-Discussions-to-Supply-up-to-405-Million-Doses-of-Potential-MRNA-Based-COVID-19-Vaccine